The Rhesus story in Northern Ireland. by O'Sullivan, J. F.
THE RHESUS STORY IN NORTHERN IRELAND
by
JOHN F. O'SULLIVAN, MB, BCh, FRCS, FRCOG
Consultant Obstetrician, Royal Maternity Hospital, Belfast
IN the last four decades the Rhesus problem has been defined; its cause then
identified, leading on to a rational treatment which for a time was available to the
baby after birth but later extended to the baby before birth; culminating in the
grand finale-disease prevention. Unfortunately that grand finale, despite the
optimism of the seventies, had not yet been reached.
DISCOVERY OF THE RHESUS BLOOD GROUP
For many years, doctors had realised that there was a heterogeneous group of
newborn babies who developed jaundice, anaemia or both, which were variants of a
single underlying disorder, characterised by haemolysis and erythroblastosis. In
1940, Landsteiner and Wiener' published a paper of less than 20 lines in which they
described the discovery of the Rhesus blood group system. In the following year
Levine2 reported that haemolytic disease ofthe newborn or in some casesa stillbirth,
was due to incompatibility between mother and fetus.
The next developments took place in England where Fisher,3 working in
Cambridge, predicted and later proposed an alternative notation to the Rh/hr
suggested by Wiener. His CDE/cde notation is now accepted throughout the world.
Coombs,4 working in the same laboratory, developed a technique for detecting
Rhesus antibodies. This test is also used throughout the world.
Seventeen per cent of women in the British Isles are Rhesus negative, and lack of
this antigens is designated by the letters d/d. It has been calculated' that three ofthe
seventeen will marry Rhesus negative husbands, six will marry homozygous Rhesus
positive (D/D) husbands with a 1:12 chance of the second child being affected,
while eight will marry heterozygous Rhesus positive (D/d) husbands with a chance
of the second baby being affected in 1:15.
CLINICAL BACKGROUND
Before the introduction of Rhesus prophylaxis the incidence of the disease was
1:200 of all pregnancies. Rhesus negative women became sensitised during the first
pregnancy, usually during the third stage oflabour as the placenta separated. Minor
degrees of placental separation may occur during pregnancy, e.g., threatened
abortion, antepartum haemorrhage during external cephalic version and amnio-
centesis, and play a part in the sensitisation ofa small number ofpatients. Following
sensitisation, in any subsequent pregnancy, ifthe fetus is Rhesus positive, antibodies
will be produced. Formerly, blood transfusion had been a major factor in the
production of antibodies. Donald5 reported that pre-1950 over one-third of all
patients with antibodies gave a history of blood transfusion.
For many years the only treatment available was a direct transfusion of blood to
the baby after birth-often the father's Rhesus positive blood being used! Rhesus
negative blood was given after its discovery. Wallestein6 in New York described the
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needle into the superior saggital sinus and a second needle into the umbilical vein.
The "exchange" transfusion as performed today only became a reality after the
development of the plastic tubing and its introduction into medical practice. In
1947, Diamond7 brought samples of tubing to Britain and introduced the exchange
transfusion. The first such transfusion was performed in Belfast in 1948.8
The perinatal mortality remained high so premature induction of labour was
considered as another means of improving the results. The Medical Research
Council initiated a multicentre controlled trial into the management ofpatients with
antibodies. Two problems were considered- 1) the routine induction of premature
labour at three or five weeks before term versus the onset of spontaneous labour,
and 2) exchange transfusion versus direct transfusion to the baby. Northern Ireland
was represented on the supervising committee by Dr W.A.B. Campbell and all
patients in the Belfast teaching hospitals were used in the trial. The results are shown
in Table I. The authors9 concluded that babies born spontaneously at term had a
lower mortality than those born prematurely and that exchange transfusion was a
better form of treatment than simple direct transfusion.
TABLE I
Results ofM.R.C. trial 1952. Fetal loss due to Rhesus disease
Exchange transfusion 13.0%
Direct transfusion 37.0Gb
Routine induction oflabour 36.401o
Spontaneous onset oflabour 24.1%
THE LOCAL SCENE
In July 1948, the National Health Service was established. No consultant
obstetricians had been based outside Belfast nor were maternity beds available apart
from those in the Belfast hospitals. Thus, in 1948, there were only 12 patients with
antibodies delivered in the Royal Maternity Hospital, Belfast. The importance of
centralisation and the need for paediatric help was obvious. As consultant
obstetricians were appointed to peripheral hospitals, patients with antibodies were
transferred to Belfast for treatment. In 1956, 63 patients with antibodies had been
delivered in the Royal Maternity Hospital, and 15 babies born elsewhere admitted
for treatment, while in Jubilee Maternity Hospital 32 patients were delivered and 6
infants transferred for treatment.8
Professor C.H.G. Macafee did not accept theresults ofthe MRC trial and instead
advocated a policy of selective induction of premature labour. His views were
supported by Kelsall and Vos'0 who reported a loss of only 10.7 per cent in infants
delivered by premature induction oflabour, compared with a loss of23.4 per cent in
those delivered spontaneously at term. Fisher"I published a series from Royal
Maternity Hospital which showed that selective planned induction of labour-as
distinct from the MRC routine induction oflabour-resulted in a lower fetal loss of
9516 per cent as compared with 29 per cent in a similar group delivered at term
(Table II). Fisher also pointed out that those infants delivered following induction
of labour were from mothers with a bad Rhesus history and required twice as many
exchange transfusions as those delivered at term. Campbell'2 reported that a high
potassium level in stored citrated blood had toxic effects on many babies during
exchange transfusion and recommended that freshly collected heparinised blood
should be used for the exchange transfusion.
TABLE II
Fetal loss due to Rhesus disease, RoyalMaternity Hospital, Belfast, 1957
Selective induction oflabour 16.0Gb
Spontaneous onset oflabour 29.0%
In selecting patients for induction of labour, Professor Macafee admitted such
women not later than the thirty-sixth week of the pregnancy. The indications for
induction were, to a certain extent, arbitrary, e.g., the history of a previously
affected or stillborn infant due to haemolytic disease, a rising antibody titre and a
homozygous Rhesus positive father were important factors. During the latter weeks
of pregnancy any diminution of fetal movements reported by the patient or an
alteration in the fetal heart noted by the midwife were indications for immediate
delivery.
CONTINUING RESEARCH
Obviously there was a need for a specific test to help in selecting patients for
induction of labour. In 1950, Bevis'3 in Manchester commenced studies on the
liquor obtained byhindwater rupture at thetime ofinduction oflabour. In 1956's he
reported that measurement of the bilirubin content of the liquor obtained by
amniocentesis during the pregnancy was the best indicator of fetal wellbeing. This
test has become the yardstick by which the severity of the disease is measured. The
test was improved by Liley'3 who in turn produced the results on a graphic form in
which the degree ofseverity ofthe affected fetus was recorded in threezones-mild,
moderate and severe. Amniocentesis in the management ofpatients with antibodies
was introduced in the Waveney Hospital by Vernon Parry,'6 a former colleague of
Bevis.
Amniocentesis is not without risk. In a series of 410 amniocentesis performed
prior to placental localisation, Peddle'7 reported that transplacental haemorrhage
from fetus to mother occurred in 11.2 per cent. Placental localisation by ultrasound
reduces the risk. In the Royal Maternity Hospital, in 1977, despite the use of
ultrasound, transplacental haemorrhagewas reported in 20out of128 amniocenteses
performed on women with antibodies. Obviously, in these 20patients thisdiagnostic
test made the condition worse.
The diagnosis of transplacental haemorrhage could only be made after the
introduction of a technique to demonstrate fetal cells in the maternal blood.'8 This
test was perfected but was not specifically described in the management of Rhesus
patients. Zipursky '9 in Winnipeg was the first to apply this test to maternal blood
after delivery.
96OTHER TREATMENT
About the late 1950's phototherapy was introduced into the management of the
babies. This treatment followed the observation of a ward sister who noted that
jaundice faded quickly in those babies who had been exposed for a short time to
sunlight. Though there seems no doubt that this is true, the consensus of opinion
seems to be that the therapy is of more benefit in jaundice associated with pre-
maturity than in that due to Rhesus disease'20
Liley2" published details ofthe use ofintra-uterine fetal transfusion in an effort to
prevent stillbirth or the delivery ofvery severely affected babies. This procedure was
enthusiastically adopted in many centres. In 1964 the first such procedure was
performed in Jubilee Maternity Hospital, Belfast.22 In the following year the first
intra-uterine transfusion was performed in Royal Maternity Hospital.23
In an attempt to protect the baby from high levels ofantibodies while in utero the
technique ofplasmapharesis was introduced. The results are difficult to evaluate, as
other methods of treatment are also given simultaneously, e.g., intra-uterine fetal
transfusion. It is possible, however, that repeated plasmapharesis lowers the affinity
ofthe Rhesus antibody and this mayexplain the apparent success ofthe procedure.24
The method was not found rewarding in Belfast.
In 1968, Whitfield25 introduced his "Action Line" which was superimposed on
Liley's zones. While Liley had predicted the severity of the disease, different
managements ofthe patient were advocated by various workers. Whitfield based his
recommendation on the results of two bilirubin estimations. This was later
modified26 when liquor studies of the lecithin sphingomyelin area ratio (LSAR)
became available. This test is used to estimate the maturity of the fetal lungs.
Obviously, if the result was good the baby could be delivered knowing that there
would be no respiratory problems in addition to the haemolytic problem. Likewise,
if the test was poor then intra-uterine fetal transfusion was needed. The number of
intra-uterine transfusions in Royal Maternity Hospital is shown in Table III. The
dramatic fall is due mainly to the changes in management and the virtual disappear-
ance of the "grand multipara".
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The extraordinary story of how an amateur interest in butterflies which had led
Clarke27 to start work on genetics which eventually turned from butterflies to the
human blood groups is well known. This led to the discovery that fetal Rhesus-
positive cells in thematernal blood could bedestroyed byadministering anti-D in the
97form ofgammaglobulin to the mother in the puerperium. At about the same time in
the United States of America, Freda et al28 were achieving similar clinical results,
although they had arrived at their conclusions by a different route. Their story is no
less bizarre-using volunteers from Sing-Sing Prison as their original subjects.
Routine prophylaxis by the injection of 100 mg of anti-D gammaglobulin within
72 hours of delivery to a Rhesus negative woman who had been delivered of a
Rhesus positive baby was introduced in 1970.29 In 1968 this was given to selected
patients following delivery. This was due to the small volume of supplies available.
Only in 1971 was routine prophylaxis made available here to all women who
required this treatment. The dramatic fall in the number of women with antibodies
delivered in Royal Maternity Hospital is shown in Table IV. This is mainly due to
prophylaxis but also to the ready availability of contraceptive advice.
TABLE IV
Patients delivered in RoyalMaternity Hospital, Belfast
Date Total Affected Fetal loss
1948 12 7 57%
1955 67 54 31%
1968 237 161 19%
1975 116 65 26%
1981 43 36 11%
The Standing Medical Advisory Committee Report on the Prevention of Rhesus
Disease" recommended that anti-D be given after spontaneous abortions. This had
not been the practice in Northern Ireland. An addendum recommending further
indications for the use of-anti-D is currently being considered. This would include
indications such as routine prophylaxis after external cephalic version, etc.
Some women are still developing antibodies. McClelland and McLoughlin3'
reported some disturbing figures from the province (Table V). Obviously, there is
room for improvement as some of the patients did not receive anti-D. This applies
particularly to those women who abort at home before their blood group is known
and to those few women who are delivered at home. With the present methods it is
accepted that prophylaxis will fail in 2 per cent of those women who have received
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98the gammaglobulin. In several countries this has been reduced by the administration
of anti-D during the pregnancy. Figures from Canada, United States, Sweden and
Australia show that the failure rate can be reduced to 0.2 per cent.32 However, the
authors use varying quantities of anti-D and administer it at different times during
the pregnancy. Their recommendations would require a fourfold increase in the
amount of anti-D gammaglobulin required. In the United Kingdom, a further
clinical trial, using anti-D during pregnancy is in progress in several centres.
OTHER RHESUS ANTIBODIES
There are a small number of patients with antibodies other than D. There is no
prophylaxis against these. It is of interest that there has been no drop in the
numbers. The patients from Royal Maternity Hospital have been discussed in
detail.33 Anti-E has not been a problem but C and c antibodies may severely affect
the fetus and the patients must be carefully supervised. It should be noted that thse
antibodies may be found in Rhesus positive patients. Obviously, as prophylaxis
against the D antibody continues these others will eventually form the major part of
the problem.
CONCLUSION
The story of the Rhesus disease is fascinating, especially as so much, from
diagnosis to prevention, has taken place in a very short time. Doctors from many
countries have contributed to this. The importance of "teamwork" has been
shown-obstetrician, neonatologist, haematologist and physician combining to
produce a good end result. Northern Ireland doctors have played an important role
in influencing opinion in the United Kingdom.
Complacency must not develop while that "grand finale"-elimination of all
anti-D antibodies-has not yet been achieved. We must continually be on our guard
to ensure that anti-D gammaglobulin is always given when required and we await the
recommendations of the present British research workers which will reduce the
disease even further.
REFERENCES
I Landsteiner K, Weiner AS. An agglutinable factor in human blood recognised by an immune sera for
rhesus blood. Proc Soc Exp Biol Med 1940; 43: 223.
2 Levine P, Katzin EM, Burnham I. Isoimmunization during pregnancy; its possible bearing on the
etiology of erythroblastosis fetalis. JA MA 1941; 116: 825-827.
3 Race RR. An "incomplete" antibody in human serum. Nature 1944; 153: 771-772.
4 Coombs RRA, Mourant AE, Race RR. Detection of weak and "incomplete" Rh agglutinins: a new
test. Lancet 1945; ii: 15-16.
s Donald I. Practical Obstetric Problems, 5th edition; London: Lloyd-Luke, 1979.
6 Wallestein H. Treatment of severe erythroblastosis by simultaneous removal and replacement of the
blood of the newborn infant. Science 1946; 103: 583-584.
7 Diamond LK. Erythroblastosis fetalis or haemolytic disease ofthe newborn. ProcRoy SocMed 1947;
40: 546-550.
8 Campbell WAB. Fetal loss in haemolytic disease of the newborn. Ulster Med J 1957; 26: 179-185.
9 Mollison PL, Walker W. Controlled trials of the treatment of haemolytic disease of the newborn.
Lancet 1952; 1: 429-433.
10 Kelsall GA, Vos GH. Premature induction of labour in the treatment of haemolytic disease of the
newborn. Lancet 1955; H: 161-164.
99I Fisher OD. Influence of selective induction of labour on mortality in haemolytic disease of the
newborn. BrMed J 1957; 1: 615-617.
12 Campbell WAB. Potassium levels in exchange transfusion. Arch Dis Childh 1955; 30: 513-516.
13 Bevis DCA. Composition of liquor amnii in haemolytic disease of the newborn. Lancet 1950; 1i: 443.
14 Bevis DCA. Blood pigments in haemolytic disease of the newborn. J Obstet GynaecolBrEmp 1956;
63: 68-75.
15 Liley AW. Liquor amnii analysis in the management of the pregnancy complicated by Rhesus
sensitization. Am J Obstet Gynaecol 1961; 83: 1359-70.
16 Vernon-Parry J. Personal communication 1964.
17 Peddle IJ. Increase in antibody titre following amniocentesis. Canad Med Assn J 1968; 97: 1245.
18 Kleihauer E, Braun H, Betke K. Demonstration von fetalen hamglobin in den erythrocyten eines
blutausstricks. Klin Wochenschr 1957; 35: 637-638.
19 Zipursky A, Hull A, White FD, Israels LG. Fetal erythrocytes in the maternal circulation. Lancet
1959; 1: 451-452.
20 Cremer RJ, Perryman PW, Richards DH. Influence of light on hyperbilirubinaemia of infants.
Lancet 1958; 1: 1094-97.
21 Liley AW. Intra-uterine transfusion of the fetus in haemolytic disease. BrMed J 1963; U: 1107.
22 Sloan WR, Slattery C, McGimpsey M. Transamniotic transfusion ofthe fetus for haemolytic disease.
Nurs Mirror 1965; 120: 5-8.
23 Harley JMG. Personal communication 1982.
24 Fraser ID, Bothamley JA, Bennett MO, Airth GR, Lehane D, McCarthy M, Roberts FM. Intensive
antenatal plasmaphoresis in severe Rhesus immunization. Lancet 1976; 1: 6-9.
25 Whitfield CR, Neely RA, Telford ME. Amniotic fluid analysis in Rhesus iso-immunization. JObstet
Gynaecol Br Commonw 1968; 75: 121-127.
26 Whitfield CR. Rhesus haemolytic disease. J Clin Path 1976; 29 Suppl 10: 54-62.
27 Clarke CA, Finn R, Donohoe WTA, McConnell RB, Sheppard PM, Lehane D, Kulke W.
Experimental studies on the prevention of Rhesus haemolytic disease. Br Med J 1961; i: 1486.
28 Freda VJ, Gorman JG, Pollack W. Successful prevention ofexperimental Rhesus sensitization in man
with an anti Rhesus gammaglobulin antibody preparation. Transfusion 1964; 2: 26-32.
29 Medical Research Council. Controlled trial of various anti-D dosages in suppression of Rhesus
sensitization following pregnancy. BrMed J 1974; H: 75-80.
30 Standing Medical Advisory Committee. Memorandum on haemolytic disease of the newborn.
London: HMSO, 1976.
31 McClelland WM, McLoughlin KG. Prevention of Rhesus (D) immunization. Some causes of failure
in Northern Ireland. Ulster MedJ 1980; 49: 148-152.
32 McMaster Conference on Prevention of Rhesus Immunization. Vox Sanguins 1979; 35: 50-64.
33 Dornan JK. Non "D" Rhesus and irregular antibodies-an approach to management. Irish Med J
1982; 75: 79-82.-